Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Rexlemestrocel-L (Primary)
- Indications Heart failure
- Focus Adverse reactions; Therapeutic Use
- 14 Sep 2017 Planned End Date changed from 1 Jan 2019 to 1 Aug 2019.
- 14 Sep 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Aug 2018.
- 30 Aug 2017 Status changed from recruiting to active, no longer recruiting.